No rise in serious HF seen in patients taking saxagliptin or sitagliptin

Neither saxagliptin nor sitagliptin, the two oral DPP-4 inhibitors most commonly used as antihyperglycemic medications, raised the risk of hospitalization for heart failure in a large...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news